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A B S T R A C T
There are now emerging data to support the association between inflammation and 
atrial fibrillation (AF). Initial observations were made after coronary artery bypass 
surgery, noting a peak incidence of AF on the second and third post-operative days, 
which coincided with the peak elevation of CRP levels. This association was subse-
quently shown in several other situations of AF. Data also emerge which link the re-
nin-angiotensin aldosterone system (RAAS) to this inflammatory process. A putative 
link between inflammation and thromboembolic complications of AF has also been 
suspected. Given the important role of the RAAS in inflammation and AF, it could 
be postulated that interruption of the RAAS may exert positive effects upon this pro-
cess. Statins with their anti-inflammatory action as part of their pleiotropic effects, 
as well as other anti-inflammatory agents, such as steroids and fish oils, might be of 
help in AF therapy according to some clinical studies. Finally, there appears to be a 
connection with atrial fibrosis in AF, as increased atrial fibrosis has been shown to 
correspond to an increase in conduction heterogeneity and AF vulnerability. Thus, 
inflammation and fibrosis may constitute new therapeutic targets in the management 
of AF. More studies are needed to clarify these important issues.
I N T R O D U C T I O N
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in 
clinical practice, affecting approximately 0.9% of the population.1 The prevalence of 
AF is strongly age-dependent, affecting approximately 1% of persons aged 65 years 
and 5% of individuals older than 65 years.2 AF is also associated with an increase in 
the relative risk of mortality ranging from 1.3 to 2.34, independent of other risk factors 
as well as an increasing morbidity and adversely affects quality of life.3-5Unfortunately, 
current rhythm control strategies are far from ideal. Data from five comparative stud-
ies of a primary rate control vs. rhythm control strategy for patients with a history of 
AF failed to show a significant superiority of rhythm control.6-10 In fact, these studies 
merely emphasized the limited efficacy and high side-effect profile of the currently 
available anti-arrhythmic drugs.11
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I N f l A m m A T I O N  A N D  A T R I A l  f I B R I l l A T I O N
There is now an increasing body of evidence linking in-
flammation to a broad spectrum of cardiovascular conditions, 
such as coronary artery disease (CAD), insulin resistance and 
diabetes mellitus, and hypertension.12-16 In addition, there is 
emerging data to support the association between inflamma-
tion and AF.17-18
The pathophysiology of AF is highly complex. It is now 
recognized that the development of AF leads to functional 
changes within the atria that perpetuate the arrhythmia (‘AF 
begets AF’), by a process known as electrical remodeling.19 
Structural remodeling of the atria occurs in parallel with the 
changes of electrical remodeling. The structural changes which 
define this structural remodeling include left atrial dilatation 
and increasing atrial fibrosis.20 Key to this fibrotic process is the 
deposition of increased amounts of connective tissue between 
individual cells and with the deposition of large amounts of col-
lagen and fibronectin.21 Bruins et al. were the first to propose 
the inflammation-AF hypothesis, following their observations 
of an increased frequency of AF after coronary artery bypass 
surgery. They noted that the peak incidence of AF occurred 
on the second and third post-operative days, which coincided 
with the peak elevation of CRP levels.22
Histological evidence to support the association be-
tween inflammation and AF has been derived from several 
sources.23-27 Results of atrial biopsies taken from patients 
in AF compared with controls have demonstrated evidence 
of inflammatory infiltrates and oxidative damage within the 
atrial tissue. The inflammatory markers that have been most 
frequently studied are high-sensitivity C reactive protein (hs-
CRP) and interleukin (IL)-6. Levels of hs-CRP have been 
noted to be higher among patients with AF compared with 
controls in sinus rhythm. Also, persistent AF patients have 
higher hs-CRP levels than paroxysmal AF patients, and both 
have higher levels than controls.28-35 Furthermore, a longer 
duration of AF is associated with higher hs-CRP levels and 
larger left atrial dimensions, supporting a link between the bur-
den of AF, inflammation, and structural remodelling. In both 
cross-sectional and longitudinal studies, hs-CRP has remained 
a consistent and significant predictor of early AF relapse after 
successful cardioversion, even after adjustment for risk factors 
for AF, such as hypertension and CAD. hs-CRP has also been 
shown to be predictive of subsequent future development of 
new cases of AF among a large cohort of patients in sinus 
rhythm.30-32,34 IL-6 levels would be raised in patients with AF 
compared with healthy controls.
There have been five studies which have investigated the 
relationship between IL-6 and AF. Four of these studies found 
increased levels of IL-6 in patients with AF compared with 
healthy controls, with one failing to find any association.28-30,35,36 
So far, there has been only one study that has looked into the 
possible association between TNF-a and AF. This was a very 
small study and did not adjust for confounding factors; how-
ever, it did demonstrate increased levels of TNF-a in patients 
with AF compared with healthy controls in sinus rhythm.28 
Finally, there appears to be a relationship between elevated 
white blood cell count as a marker of inflammation and the 
development of AF after cardiac surgery in 181 consecutive 
patients undergoing coronary bypass or cardiac valve surgery 
(AF), even after multivariate analyses.37
There is histological evidence to confirm that AF (both 
persistent and paroxysmal) leads to altered angiotensin II 
receptor expression. In a key paper, Cardin et al. were able to 
link increased atrial expression of angiotensin II receptors with 
increased atrial cell death and leukocyte infiltration supporting 
a potential link between the RAAS, inflammation, and AF. 
Furthermore, there is now evidence linking polymorphisms 
in the renin–angiotensin system (RAS) gene with an increase 
risk of subsequent AF development, further supporting the 
role of the RAAS in the development of AF.38-43
Although there appears to be a link between inflamma-
tion and AF, one of the key questions is whether the observed 
inflammation in AF increases the risk of thromboembolism as 
has been demonstrated for atherosclerotic models. Conway et 
al. were the first to confirm this putative link between inflam-
mation and complications of AF. In a small pilot study, they 
showed that elevated IL-6 levels were an independent predic-
tor of the composite of stroke or death among a cohort of 77 
high-risk AF patients.44 This observation was complemented 
by data from Thambidorai et al, which showed that trans-es-
ophageal risk factors for stroke were greater for patients with 
elevated hs-CRP compared those with normal levels among 
104 patients with AF.45 Hence, there appears to be an estab-
lished link between inflammation, AF, and thrombosis.
P R e v e N T I N g  A f  B y  m O D U l A T I N g  
T h e  I N f l A m m A T O R y  S T A T e
There have been a large number of studies that have 
analyzed the relationship between RAAS inhibition and Af. 
In a recent large meta-analysis (56308 patients) incorporating 
11 of the 12 randomized trials using either ACE-inhibitors or 
ARBs for the prevention of AF, Healey et al. demonstrated a 
favorable effect of RAAS inhibition in the primary and second-
ary prevention of AF. They concluded that ACE-inhibitors/ 
ARBs reduced the overall risk of AF by 28% [95% confidence 
interval (CI) 15–40%, P: 0.0002] across a broad spectrum of 
patient subgroups (including patients with hypertension, heart 
failure, post-myocardial infarction, and post-cardioversion). 
Furthermore, the reduction in AF was similar independent 
of whether an ACE-inhibitor or an ARB was the main drug 
group used (ACE-inhibitors: 28%, P:0.01; ARBs: 29%, P: 
0.00002).46
There have been several putative mechanisms to explain 
the favorable actions of ACE-inhibitors and ARBs in the pre-
vention of AF: decreased atrial stretch; lowered end-diastolic 
left ventricular pressure and subsequent left atrial pressure; the 
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cardioversion was adopted in all of the patients as part of the 
trial protocol. All patients were successfully cardioverted and 
were commenced on oral propafenone post-cardioversion. 
The authors found that methyl prednisolone significantly 
reduced the primary endpoint of AF recurrence (50% in the 
placebo group vs. 9.6% in the glucocorticoid group) as well as 
the extended endpoint of permanent AF (29% in the placebo 
group vs. 2% in the glucocorticoid group). In addition, hs-CRP 
concentrations were a significant predictor of the primary 
end-point, with higher hs-CRP levels being predictive of AF 
recurrence, and vice versa. In addition, methyl prednisolone 
significantly lowered hs-CRP by an average of 80% within 
the first month, and this reduction was maintained for the 
duration of the 30-month study (P=0.001). The authors also 
demonstrated that the risk of AF recurrence was increased by 
approximately seven times for each 1 mg/dL increase in plasma 
levels of hs-CRP, providing a strong link between the degree 
of inflammation and the burden of AF.
f I S h  O I l S
Dietary intake of polyunsaturated fatty acids (PUFAs), 
notably omega (n)-3 fatty acids, have been to shown to have 
favorable effects on cardiovascular outcomes. Their efficacy 
can only be partly explained by improvement in lipid profile 
and there is mounting evidence to support potential anti-
inflammatory and antioxidant properties of oily fish. Indeed, 
n-3 fatty acids have anti-inflammatory properties and are 
frequently used clinically to treat symptoms of inflammatory 
diseases, such as rheumatoid arthritis or Crohn’s disease.57,58 
In a prospective, population-based cohort of 4815 older (>65 
years) Mozaffarian et al. demonstrated that consumption of 
high levels of fish containing n-3 fatty acids was associated with 
a lower incidence of subsequent AF development.59 However, 
these results are challenged by an even larger prospective study 
of 47 949 participants (mean age: 56 years) which investigated 
the relation between the consumption of n-3 fatty acids from 
fish, by use of a detailed semi-quantitative food questionnaire, 
and risk of AF or flutter, but found that consumption of n-3 
fatty acids from fish was not associated with a reduction in risk 
of AF or atrial flutter.60 Finally, in a recently published study 
of 160 patients pre-treatment with omega-3 fatty acids reduced 
the incidence of AF post-coronary artery bypass surgery by 
58% compared with patients treated with usual care only.61 
In this study, 2 g/day of PUFAs was administered at least 7 
days before surgery and continued until discharge. In addition, 
treatment with fish oils reduced the length of hospitalization 
from 8.2 to 7.3 days (P:0.017).
v I T A m I N  C
Ascorbic acid (vitamin C) is potent oxygen scavenger, 
which may potentially modulate the inflammatory and oxi-
dative abnormalities associated with AF.62 In a novel study, 
Carnes et al. gave supplemental ascorbate to 43 patients 
prevention of atrial fibrosis; the modification of sympathetic 
tone, alteration in ion currents and atrial refractoriness, and 
direct anti-arrhythmic effects.47 However, given the demon-
strated important role of the RAAS in inflammation and AF, 
it could be postulated that interruption of the RAAS may exert 
positive effects upon the left atrium by reducing atrial inflam-
mation, oxidative stress, and reduce atrial remodelling.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors, remain the most powerful and effective lipid-lower-
ing drugs. A series of landmark clinical trials have established 
statins as effective agents in the primary and secondary pre-
vention of coronary artery disease. It has become increasingly 
apparent that the benefits of statins extend to mechanisms 
beyond their cholesterol-reducing effects. These ‘pleiotropic’ 
(multiple) effects include improved endothelial function with 
increased nitric oxide bioavailability, anti-thrombotic effects, 
enhanced stability of the atherosclerotic plaque, and decreased 
oxidative stress and vascular inflammation. If AF is indeed 
linked to inflammation then statins would offer a potentially 
preventative role in AF. There have been five studies so far 
that have analyzed the efficacy of statins in the prevention of 
AF.48-52 Four of these studies showed favorable effects of statins 
to reduce the incidence of AF, with only one study reporting 
negative results. Siu et al were the first to study the prevention 
of AF with statins. They retrospectively studied 62 patients with 
lone persistent AF lasting 3 months who underwent direct cur-
rent cardioversion, and observed that statin- treated patients 
(n = 10) had less recurrent AF than the control group of 52 
patients (40 vs. 84%, P: 0.0007); however, this was a very small 
and underpowered observational study.53 In a much larger 
observational study, Young- Xu et al.166 studied a cohort of 
449 patients with CAD at high risk of AF. They observed a 
significantly lower rate of new AF development among statin 
users (9%) compared with non-users (15%). Of note, the po-
tential impact of statins on AF development was independent 
of its cholesterol-lowering ability. Also, the efficacy of statins 
in preventing AF appeared to correlate with the length of 
statin use, with longer statin use being associated with greater 
protection against the subsequent development of AF.54 In 
the largest study so far, Hanna et al. performed a cross-sec-
tional analysis of 25,000 patients enrolled in the multicenter 
Guidant-sponsored Advancement Heart Failure Registry; of 
these patients, 7027 patients (27%) developed AF, and statin 
therapy led to a 23% reduction in AF, when compared with 
those not treated, even after multivariate analysis (odds ratio 
for AF 0.685; P , 0.001).55
S T e R O I D S
In a double-blind study, Dernelis and Panaretou rand-
omized 104 patients with first presentation persistent AF to 
low-dose glucocorticoid therapy (16 mg methyl prednisolone 
for 4 weeks tapered to 4 mg for 3 months) or placebo.56 A 
primary rhythm control strategy involving amiodarone & 
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useful in delaying progression of atrial fibrosis and AF.
In a transgenic mouse model that overexpresses a consti-
tutively active transforming growth factor TGF-β1, selective 
atrial interstitial fibrosis was observed, but ventricular histology 
was normal. This occurred despite equal over-expression of 
TGF-1 in the atrium and the ventricles. The increase in atrial 
fibrosis was shown to correspond to an increase in conduction 
heterogeneity and AF vulnerability.72 Cellular electrophysiol-
ogy was not affected by the TGF-β1. This study demonstrated 
that atrial fibrosis alone is a sufficient substrate for AF, and 
that TGF-β1 may play an important role in the genesis of atrial 
fibrosis. In another study by the same group, the drug pirfeni-
done was used to target the expression of TGF-β1. Pirfenidone 
has been shown to significantly reduce expression of TGF- β1, 
with a concomitant reduction in tissue fibrosis in multiple 
experimental animal models.65 Increases in angiotensin II (An-
gII) and activated TGF-β1 concentrations reciprocally enhance 
each other’s production73 and induce expression of additional 
profibrotic molecules in fibroblasts74 creating positive feed-
back cycles for fibrosis. Mechanical stretch induces collagen 
synthesis75 along with increased AngII and TGF-β1 expression 
in cardiac fibroblasts,76 and thus chronic atrial dilation may 
contribute to structural remodeling and the domestication of 
AF.77 Fibroblast stretch- sensing mechanisms show exquisite 
sensitivity, with different types of deformation causing dif-
ferential ECM expression profiles. In addition to profibrotic 
actions, mechanical stretch of fibroblasts can directly modulate 
myocyte electrical activity, a potentially proarrhythmic mecha-
nism called mechanoelectric feedback.78
C O N C l U S I O N
Inflammation and fibrosis play an important role in the 
development of AF. Therefore inflammation and fibrosis may 
constitute new therapeutic targets in the management of AF. 
More studies are needed to clarify these important issues.
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